CD274 and neoplasm: The importance of cDC1 in oncologic immunity is highlighted by the abolishment of tumor rejection and responsiveness to adoptive T cell therapy and immune checkpoint blockade in mice lacking cDC1 (89, 90) and it has been shown that induction and activation of tumor-residing cDC1s can help overcome resistance to anti-PD-L1 therapy (91).